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ABSTRACT
Background:
There are controverted whether the long-term use of proton pump inhibitors (PPI) will 
increase the risk of gastric cancer. We performed a meta-analysis to assess the risk of 
gastric cancer in PPI users compared with non-PPI users.
Methods:
The main inclusion criteria were original studies reporting the incidence of gastric 
cancer in PPI users compared with non-PPI users. Key outcomes were the risk ratios 
(RR) for gastric cancer in association with PPI users or non-PPI users. 
Results:
We analyzed data from 8 studies, comprising more than 927,684 patients. The risk of 
gastric cancer in PPI users was signiﬁ cantly higher than in non-PPI users [RR= 2.10, 
95% CI (1.17-3.97)]. The risk of gastric cancer was similar between the 2 groups when 
the duration was ≤1 year [RR= 2.18, 95% CI (0.66-7.11)]. While the risk of gastric 
cancer for PPI users was higher than in non-PPI users when the duration was between 
1-3 years, ≥1 year, ≥3 years and ≥5 years. The risk of non-cardiac gastric cancer for PPI 
users was higher than for non-PPI users [RR= 2.66, 95% CI (1.66 -4.27)], and the risk 
of non-cardiac gastric cancer for PPI users was higher than for non-PPI users when the 
duration ≥1 year [RR= 1.99, 95% CI (1.03-3.83)], but the risk for cardiac gastric cancer 
was similar between the 2 groups [RR= 1.86, 95% CI (0.71-4.89)].
Conclusions:
We found the long-term use of PPI (duration ≥1 year) was signiﬁ cantly associated with 
a higher risk of non-cardiac gastric cancer. 
Key words:
proton pump inhibitors; gastric cancer; Helicobacter pylori infection; long-term use
© The Author(s) 2020. Published by ED Marketing & Communication. All rights reserved.
Lin J-L, et al./ JGS 2 (2020) 1-11
doi:10.36159/jgs.v2i1.17
www.journalofgastricsurgery.com
Background:
Since the introduction of the proton pump inhibitor 
(PPI) in the late 1980s[1], the outcomes of gastric acid-
related diseases have signiÀ cantly improved. This 
innovation has signiÀ cance in the treatment of gastric 
acid related diseases[2, 3]. Due to the outstanding 
efÀ cacy and safety of PPIs, they have been widely used 
in clinical practice. The quantity of the prescriptions 
is increasing, and potential adverse effects have also 
attracted much attention. An increasing in the number 
of case reports and observational studies on the adverse 
events in patients receiving long-term PPI therapy had 
been reported. Currently, the most prominent concerns 
about long-term PPI use relate to the risks of bone 
fractures, enteric infection, pneumonia and vitamin B12 
deÀ ciency[4-7]. In recent years, studies[8] have shown 
that the long-term use of PPIs may increase the risk of 
gastric cancer, but these studies[9-11] are controversial. 
Helicobacter pylori (H. pylori) infection is one of the 
risk factors leading to gastric cancer, and PPIs are one 
of the major drugs used for the treatment of H. pylori. 
The inÁ uence on the occurrence of gastric cancer needs 
further research. Therefore, the aim of this study is to 
assess the association between PPI use and risk of gastric 
cancer through systematic reviews and meta-analyses.
Methods:
All the search results were evaluated according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement[12].
Inclusion criteria and exclusion criteria
The inclusion criteria are as follows: (1) RCTs or 
observational studies including cohort and case-control 
studies; (2) outcomes of PPI users were compared with 
those of non-PPI users; (3) studies provided adequate 
data that enabled the estimation of risk ratio (RR), odds 
ratio (OR), incidence rate ratio (IRR), and standardized 
incidence ratio (SIR). The exclusion criteria are as 
follows: (1) The article is a duplicate; (2) inadequate 
data; (3) sample size less than 20.
Literature Search
We conducted a comprehensive systematic literature 
search of online databases, including PubMed, the 
Cochrane Library, Embase and clinicaltrials.gov, 
from January 1, 1987 to Nov 1, 2018 to identify all 
RCTs and observational studies. The following key 
words were used in these literature searches: “proton 
pump inhibitor”, “omeprazole”, “esomeprazole”, 
“pantoprazole”, “lansoprazole”, “dexlansoprazole”, 
“rabeprazole”, “gastric cancer”, “gastric carcinoma”, 
“gastric adenocarcinoma”, “gastric neoplasm”, gastric 
neoplasia”, “stomach cancer”, “stomach carcinoma”, 
“stomach adenocarcinoma”, “stomach neoplasm”, 
and “stomach neoplasia”. There were no language 
restrictions. We also reviewed the references of the 
included articles and related systematic reviews to 
identify additional studies.
Study Selection and Quality Assessment 
The quality of included non-RCTs was assessed using 
the Newcastle–Ottawa Scale (NOS) [13]. The scale 
used a score system, which ranged from 0 to 9, and the 
quality of the observational studies were enrolled if they 
achieved 6 or more.
Data Extraction
Data extraction and the evaluation of literature quality 
were conducted independently by 2 investigators (Ju-li 
Lin and Jian-xian Lin). When there was any uncertainty 
about the inclusion of a study, the issue was discussed 
between the two investigators to achieve a resolution. 
In cases of disagreement, the qualitative analysis was 
performed by Chao-Hui Zheng. A Microsoft Excel 
database was used to record all available information, 
including baseline details, title, À rst author’s name, year 
of publication, study design, region, journal, sample 
size, period of patient recruitment, follow-up time, 
deÀ nition of PPI use, adjusted odds ratio (OR), risk ratio 
(RR), standardized incidence ratio (SIR), and incidence 
rate ratio (IRR) of gastric cancer.
Outcome deÀ nition
Primary outcome: the risk of gastric cancer in PPI users 
compared with non-PPI users; Secondary outcomes: the 
risk of gastric cancer when therapy duration ≤1 year, 1-3 
years, ≥1 year, ≥3 years and ≥5 years; the risk of cardia 
gastric cancer; the risk of non-cardia gastric cancer; the 
risk of gastric cancer with H. pylori infection; and the 
risk of gastric cancer with prior H. pylori infection.
Data synthesis
Because the absolute risk of gastric cancer is low, one 
can generally ignore the distinctions among the various 
measures of relative risk (e.g., odds ratio, risk ratio, 
standardized incidence ratio, incidence rate ratio)[14, 
15]. The effect estimates that were extracted, if available, 
or de novo calculated from available data were SIR, 
IRR, RR and OR. SIR was estimated as the ratio of the 
observed over expected number of cases for exposed 
patients. The 95% conÀ dence interval (CI) for loge(SIR) 
was constructed via the term”±” 1.96/[square root (O)], 
where O was the observed number of events (Alder et 
al, 2006)[16]. Maximally adjusted effect estimates (ORs) 
were additionally extracted on the total of the sample, 
wherever possible.
Statistical Analysis
The pooled risk ratio (RR) with 95% conÀ dence 
intervals (95% CIs) was estimated for dichotomous 
outcomes. Single-arm meta-analyses were performed 
for the PPI and non-PPI groups. Cumulative meta-
analyses were also performed to evaluate the stability 
of the effect sizes. The Cochran’s Q statistic and the I2 
statistics were used to assess the heterogeneity among 
all studies. Heterogeneity among studies was tested 
using Cochran’s Chi-square test and I2, in which I2 > 
50% suggested signiÀ cant heterogeneity. A random-
effects model was chosen to pool the results when I2 
> 50%, while a À xed-effects model was used when I2 < 
50%. When possible, subgroup analyses were performed 
to assess the potential impact of the duration of PPI 
exposure, tumor location and H. pylori infection. P < 
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0.05 was considered to represent statistical signiÀ cance 
(2-sided). All the statistical analyses were conducted 
using STATA, version 13.0 (Stata Corporation, College 
Station, TX).
Results:
Studies Retrieved and Characteristics
According to the previous search strategy, 977 citations 
were obtained from the online database from January 
1, 1987 to May 1, 2018. A total of 960 articles were 
excluded by viewing the titles and abstracts. The full 
texts of 17 records were read. Among the remaining 17 
records, 8 letter and 1 case-control study were removed 
(supplement reference). Finally, 8 full-text studies were 
obtained and assessed according to the eligibility criteria, 
including 4 case-control studies and 4 cohort studies, 
comprising more than 927,684 patients. The detailed 
literature search and screening process are shown in 
Figure 1. The characteristics included in the study are 
shown in Table 1, including the À rst author’s name, year 
of publication, study design, region, journal, sample 
size, period of patient recruitment patients, follow-up 
time and deÀ nition of PPI use.
The quality of 8 studies was assessed using the 
Newcastle–Ottawa Scale (NOS). Two studies achieved a 
NOS score of 6, three studies achieved a NOS score of 7 
and three studies achieved a NOS score of 8 (Table 2). Six 
studies had a clear follow-up time, and four studies had 
a median follow-up period >3 years. The longest median 
follow-up period was 7.6 years. Six studies had a clear 
deÀ nition of the use of PPIs. Seven studies compared 
the risk of gastric cancer between PPI users and non-PPI 
users.
doi:10.36159/jgs.v2i1.17
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The risk of gastric cancer in PPI users compared with non-
PPI users
Seven studies involving 926,386 patients compared the 
risk of gastric cancer in PPI users compared with non-PPI 
users: Cheung et al[8], Garcia et al[17], Tamim et al[18], 
Niikura et al[19], Poulsen et al[20], Brusselaers et al[21], 
and Peng YC et al[22]. As shown in Figure 2A, the risk 
of gastric cancer PPI users was signiÀ cantly higher than 
non-PPI users [RR=2.10, 95% CI (1.17-3.97)]. Regional 
variations are also analyzed low-intermediate incidence 
vs high incidence. Cheung et al[8], Niikura et al[19] and 
Peng YC et al[22] is from high incidence region(HK, Japan, 
Taiwan). Garcia et al[17], Tamim et al[18], Poulsen et 
al[20] and Brusselaers et al[21] is from low-intermediate 
incidence region (UK, Canada, Denmark, Sweden). We 
found the risk of gastric cancer PPI users was signiÀ cantly 
higher than non-PPI users [RR=2.53, 95% CI (2.03-3.17)] in 
high incidence region, but no signiÀ cant differences were 
seen between the two groups [RR=1.66, 95% CI (0.95-2.89)] 
in low incidence region. The result of cumulative meta-
analysis showed that the signiÀ cant difference supporting 
PPI users was À rst found in the latest study in 2008, with 
the CI narrowing and the effect size becoming stable 
(Figure 2B).
NOTE: Weights are from random effects analysis
Overall  (I-squared = 94.3%, p = 0.000)
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Figure 2A: Forest plot of pooled risk ratio for gastric cancer in PPI users versus non-PPI users.
Garcia et al.17 2006(cardia) 
Garcia et al.17 2006(non-cardia)
Tamim et al.18 2008
Poulsen et al.20 2009
Brusselaers et al.21 2017
Peng et al.22 2018
Cheung et al 8 2018
study
1.06 (0.57, 1.99)
1.46 (1.01, 2.13)
1.46 (1.24, 1.71)
1.43 (1.23, 1.66)
1.47 (1.26, 1.70)
4.92 (4.73, 5.11)
4.84 (4.66, 5.03)
4.83 (4.65, 5.02)
RR (95% CI)
.196 5.11non-PPI users PPI users1
2B
Niikura et al.19 2017
Figure 2B: Cumulative meta-analysis of the risk ratio for the gastric cancer according to time.
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Subgroup analysis according to duration 
Duration ≤1 year: Five studies enrolled 15,494 patients 
including Garcia et al[17], Poulsen et al[20], Brusselaers 
et al[21], and Lai et al[23]. No signiÀ cant differences were 
seen between the two groups [RR=2.18, 95% CI (0.66-7.11)] 
(Figure 3).
Duration 1-3 years: Two studies enrolled 12,715 patients, 
including Garcia et al[17] and Brusselaers et al[21]. The 
risk of gastric cancer PPI users was signiÀ cantly higher 
than non-PPI users [RR=1.74, 95% CI (1.04-2.90)] (Figure 
3).
Duration ≥1 year: Four studies enrolled 93,807 patients, 
including Cheung et al[8], Garcia et al[17], Poulsen et 
al[20], and Brusselaers et al[21]. The risk of gastric cancer 
PPI users was signiÀ cantly higher than in non-PPI users 
[RR=1.88, 95% CI (1.60-2.22),] (Figure 3).
Duration ≥3 years: Four studies enrolled 93,807 patients, 
including Garcia et al[17], Poulsen et al[20], and 
Brusselaers et al[21]. The risk of gastric cancer PPI users 
was signiÀ cantly higher than non-PPI users [RR=1.95, 95% 
CI (1.65-2.31)] (Figure 3).
Duration ≥5 years: Four studies enrolled 19,323 patients, 
including Poulsen et al[20] and Brusselaers et al[21]. The 
risk of gastric cancer in PPI users was signiÀ cantly higher 
than in non-PPI users [RR= 2.03, 95% CI (1.75-2.35)] (Figure 
3).
Furthermore, the risk increased with a longer duration 
of PPI use (RR=1.74, 95% CI (1.04-2.90) for 1-3 years of 
use; RR=1.95, 95% CI (1.65-2.31) for ≥3 years of use and 
RR=2.03, 95% CI (1.75-2.35) for ≥5 years of use).
non-PPI users PPI users
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Figure 3: Forest plot of the pooled risk ratio for gastric cancer in PPI users versus non-PPI users according to duration.
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Subgroup analysis according to location
Four studies enrolled 12,294 patients, including Cheung et 
al[8], Garcia et al[17], Tamim et al[18], Brusselaers et al[21], 
and Peng YC et al[22]. The risk of non-cardia gastric cancer 
in PPI users was signiÀ cantly higher than in non-PPI users 
[RR= 2.66, 95% CI (1.66 -4.27)]. However, no signiÀ cant 
differences were found between the two groups for the 
risk of cardia gastric cancer [OR=1.86, 95% CI (0.71-4.89)] 
(Figure 4A).
In Garcia et al[17], the risk of non-cardiac gastric cancer 
for PPI users was higher than non-PPI users when the 
duration ≥1 year [RR=1.99, 95% CI (1.03 -3.83)] (Figure 4B).
Cheung et al[8], Tamim et al[18], Brusselaers et al[21] and 
Peng YC et al[22] included only gastric cancer , while 
Garcia et al[17] included only gastric adenocarcinoma.
NOTE: Weights are from random effects analysis
Overall  (I-squared = 87.7%, p = 0.000)
Tamim et al.18 2008
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Figure 4A: Forest plot of the pooled risk ratio for gastric cancer in PPI users versus non-PPI users according to location.
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Figure 4B: Forest plot of the pooled risk ratio for non-cardia gastric cancer in PPI users versus non-PPI users when duration ≥1 year.
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Subgroup analysis according to H. pylori infection
Three studies enrolled 845,923 patients, including Cheung 
et al[8], Niikura et al[19], and Brusselaers et al[21]. The risk 
of gastric cancer in PPI users was signiÀ cantly higher than 
in non-PPI users with prior H. pylori infection [RR=4.8, 
95% CI (1.82 -12.67)] (Figure 4C). 
Three studies enrolled 123,915 patients, including Cheung 
et al[8], Brusselaers et al[21], and Lai et al[23]. The risk of 
gastric cancer was similar between the two groups with H. 
pylori infection [OR= 0.91, 95% CI (0.17 -4.90)] (Figure 4c).
Cheung et al[8] included 142 460 PPIs users without prior 
H. pylori eradication therapy were identiÀ ed with a total 
of 705 094 person-years of follow-up. Niikura et al[19] 
included 571 patients who achieved H.pylori eradication 
were selected using thedatabase of University Tokyo 
Hospital from 1998 to 2017. 
Discussion:
This study included recent studies with large sample sizes 
from 1987 to 2018 to explore the risk of gastric cancer in 
PPI users compared with non-PPI users. Although all the 
included studies were retrospective studies, they were 
of were relatively high quality according to the results of 
quality evaluation and had large sample sizes. Our study 
included 8 publications with 926,386 patients, and the 
data suggested that long-term PPI use increases the risk 
of gastric cancer. Subgroup analysis suggested that long-
term PPI use may increase the risk of non-cardiac gastric 
cancer when the duration is ≥1 year. Long-term PPI use 
after H. pylori eradication therapy for patients with prior 
H. pylori infection may increase the risk of gastric cancer.
In recent years, the reported incidence rates of gastric 
cancer in PPI patients has been 0.081%-5.0%[8, 17, 20, 
21]. This rate is signiÀ cantly higher than the incidence of 
gastric cancer in the general population (0.014%-0.491%)
[24, 25]. In our study, the risk of gastric cancer in PPI 
users was also signiÀ cantly higher than that in non-
PPI users. Regional variations also be analyzed (low-
intermediate incidence (Sweden, Denmark, Canada, 
UK) vs high incidence (Taiwan, Japan, HK)). Subgroup 
analysis according to incidence, the risk of gastric cancer 
PPI users was signiÀ cantly higher than non-PPI users 
[RR=2.53, 95% CI (2.03-3.17)] in high incidence region, 
but no signiÀ cant differences were seen between the two 
groups [RR=1.66, 95% CI (0.95-2.89)] in low incidence 
region. Currently, the mechanism by which a PPI may 
increase the occurrence of gastric cancer has not been fully 
elucidated. Some studies suggest that the long-term use 
of PPIs profoundly reduces gastric acid production and 
consequently leads to the increased secretion of gastrin. 
Hypergastrinemia as a result of acid suppression causes the 
hyperplasia of enterochromafÀ n-like cells, resulting in the 
formation of microcarcinomas and gastric neuroendocrine 
tumors[26-29]. Song et al suggest that a PPI inhibits gastric 
acid and leads to hypergastrinemia, which may lead 
to hyperproliferation, chronic hypochloremia, chronic 
inÁ ammation, intestinal metaplasia and atrophy of the 
stomach [30]. In addition, a high pH environment can 
cause double infection with H. pylori and non-H. pylori 
bacterial species[31, 32].The synergistic effect of many 
bacteria can produce nitrosamine carcinogens, which may 
lead to the development of gastric cancer.
However, does the correlation between PPI use and 
gastric cancer depend on the time of treatment? Cheung et 
al [8] thought that PPIs increase the risk of gastric cancer 
development in the context of underlying H. pylori-
associated chronic gastritis and atrophy. A meta-analysis 
[33] revealed that the long-term use of PPIs (≥12 months) 
is associated with an increased risk of fundic gland 
polyps. Suissa S et al [10] thought that the correlation 
between the use of PPIs and the risk of gastric cancer may 
be caused by time bias. In this study, we found that there 
was a signiÀ cant time correlation between a PPI and the 
incidence of gastric cancer. The incidence of gastric cancer 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 99.4%, p = 0.000)
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Figure 4C: Forest plot of pooled risk ratio for gastric cancer in PPI users versus non-PPI users according to H. pylori infection.
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was signiÀ cantly higher when a PPI was used for ≥1 year.
Because of the different functional cells on different parts 
of stomach, the study found that long-term PPI use may 
increase the incidence rate of non-cardia cancer according 
to stratiÀ cation analysis of location. This may be because 
gastrin is secreted by G cells in the mucosa of the gastric 
antrum and proximal duodenum. These locations tolerate 
gastric acid well but are more prone to intestinal metaplasia 
and precancerous lesions after gastric acid suppression. In 
addition, PPIs are one of the main drugs for the treatment 
of H. pylori[4], but they are often abused. Subgroup 
analysis found that the risk of gastric cancer in PPI users 
was signiÀ cantly higher than non-PPI users with prior H. 
pylori infection, while there was no statistically signiÀ cant 
difference between PPI users and non-PPI users with H. 
pylori infection. However, while is relatively safe after 
H. pylori eradication, it is not appropriate to prescribe 
long-term PPIs to these patients, even after successful 
eradication of H. pylori.
There are also some limitations in this study. First, there is 
certain publication bias and selection bias because of the 
retrospective design of the original research. Second, the 
inconsistencies in the deÀ nition, dosage, duration, type 
of PPI use and the inclusion criteria of the original study 
may lead to bias. In addition, other potential confounding 
factors include precancerous diseases of gastric cancer, 
such as gastric polyps, gastroesophageal reÁ ux disease and 
peptic ulcers, and a family history of gastric cancer. Those 
factors have not been systematically evaluated because of 
the lack of related data. However, based on the results of 
meta-analysis, this study shows that the long-term use of a 
PPI was associated with an increased risk of gastric cancer 
development, particularly for non-cardia cancer and in 
high incidence region, which is of great signiÀ cance for 
the rational clinical application of PPIs.
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